Dako announces a collaboration with OSI Pharmaceuticals, Inc. on Companion Diagnostics
Advertisement
Dako has entered into a collaboration with OSI Pharmaceuticals, Inc. Under the terms of agreement, Dako and OSI Pharmaceuticals, Inc. will collaborate on developing a new cancer diagnostic test as a potential companion product for a cancer therapy.
The new cancer diagnostic test is intended to identify patients more likely to benefit from a specific treatment. The collaboration will draw on Dako's extensive experience within the development of cancer diagnostic tests and OSI Pharmaceuticals' thorough knowledge in developing and commercializing novel pharmaceutical products.